Abstract Number: 1769 • 2019 ACR/ARP Annual Meeting
Myosin Regulation of TNF Receptor 2 Signaling May Contribute to Anti-TNF Therapy Response
Background/Purpose: Background/Purpose:Anti-TNF agents have revolutionized the clinical outcomes of patients with rheumatoid and psoriatic diseases. However, up to 40% of patients do not respond or…Abstract Number: 1857 • 2016 ACR/ARHP Annual Meeting
A Novel Highly Selective 5-Hydroxytryptamine 2B (5-HT2B) Receptor Antagonist Ameliorating Fibrosis in Preclinical Models of Systemic Sclerosis
Background/Purpose: Methods: Results: Conclusion: The results demonstrate that the 5-HT2B receptor antagonist AM1125 prevents pro-fibrotic events in human dermal fibroblasts and attenuates…Abstract Number: 960 • 2012 ACR/ARHP Annual Meeting
Cyclobenzaprine (CBP) and Its Major Metabolite Norcyclobenzaprine (nCBP) Are Potent Antagonists of Human Serotonin Receptor 2a (5HT2a), Histamine Receptor H-1 and á-Adrenergic Receptors: Mechanistic and Safety Implications for Treating Fibromyalgia Syndrome by Improving Sleep Quality
Background/Purpose: Bedtime cyclobenzaprine (CBP) improves fibromyalgia symptoms (pain, fatigue, tenderness, and mood) and improves sleep quality (decreases Cyclic Alternating Pattern Type A2 + A3) (1).…
ACR Meeting Abstracts